LMAT official logo LMAT
LMAT 1-star rating from Upturn Advisory
LeMaitre Vascular Inc (LMAT) company logo

LeMaitre Vascular Inc (LMAT)

LeMaitre Vascular Inc (LMAT) 1-star rating from Upturn Advisory
$84
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: LMAT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

3 star rating from financial analysts

11 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $104.33

1 Year Target Price $104.33

Analysts Price Target For last 52 week
$104.33 Target price
52w Low $70.94
Current$84
52w High $104.58

Analysis of Past Performance

Type Stock
Historic Profit 7.17%
Avg. Invested days 45
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.91B USD
Price to earnings Ratio 36.21
1Y Target Price 104.33
Price to earnings Ratio 36.21
1Y Target Price 104.33
Volume (30-day avg) 11
Beta 0.67
52 Weeks Range 70.94 - 104.58
Updated Date 12/14/2025
52 Weeks Range 70.94 - 104.58
Updated Date 12/14/2025
Dividends yield (FY) 0.91%
Basic EPS (TTM) 2.32

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 22.14%
Operating Margin (TTM) 33.27%

Management Effectiveness

Return on Assets (TTM) 7.94%
Return on Equity (TTM) 15.02%

Valuation

Trailing PE 36.21
Forward PE 31.85
Enterprise Value 1748200496
Price to Sales(TTM) 7.91
Enterprise Value 1748200496
Price to Sales(TTM) 7.91
Enterprise Value to Revenue 7.26
Enterprise Value to EBITDA 20.99
Shares Outstanding 22685994
Shares Floating 20877013
Shares Outstanding 22685994
Shares Floating 20877013
Percent Insiders 7.93
Percent Institutions 95.01

About LeMaitre Vascular Inc

Exchange NASDAQ
Headquaters Burlington, MA, United States
IPO Launch date 2006-10-19
Chairman & CEO Mr. George W. LeMaitre
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 651
Full time employees 651

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.